financetom
Business
financetom
/
Business
/
Top Premarket Gainers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Top Premarket Gainers
Oct 3, 2024 4:55 AM

07:40 AM EDT, 10/03/2024 (MT Newswires) -- Pineapple Energy ( PEGY ) shares surged 61% in recent Thursday premarket activity, shaving Wednesday's 8% loss.

MicroAlgo ( VENAF ) shares were 33% higher, extending this week's rally.

Wheeler Real Estate Investment Trust ( WHLR ) stock jumped 28%, adding to the previous session's 99% surge.

Mynaric ( MYNA ) stock rose 6%, after saying overnight it amended its current $95 million loan agreement with its US-based lenders, under which the lenders will provide a $5.5 million bridge loan.

Price: 0.1880, Change: +0.07, Percent Change: +63.62

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Enbridge Provides 2025 Guidance; Raises Dividend by 3%
Enbridge Provides 2025 Guidance; Raises Dividend by 3%
Dec 3, 2024
07:42 AM EST, 12/03/2024 (MT Newswires) -- Enbridge ( ENB ) said Tuesday that it expects full-year 2025 adjusted earnings per share to be in a range of CA$5.50 to CA$5.90 ($3.92 to $4.20). Analysts polled by Factset expect $3.01 Enbridge ( ENB ) also said it raised its quarterly dividend by 3% to $0.9425 from $0.915 per share. The...
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors
Dec 3, 2024
07:45 AM EST, 12/03/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday it has entered into an exclusive option and license agreement with Tubulis to discover and develop an antibody-drug conjugate, or ADC against a solid tumor target. Gilead will receive access to Tubulis' Tubutecan and Alco5 platforms to design a Topoisomerase I inhibitor-based ADC, the company said....
Core & Main's Fiscal Q3 Earnings, Net Sales Rise; Fiscal 2024 Sales Guidance Lifted
Core & Main's Fiscal Q3 Earnings, Net Sales Rise; Fiscal 2024 Sales Guidance Lifted
Dec 3, 2024
07:45 AM EST, 12/03/2024 (MT Newswires) -- Core & Main ( CNM ) reported fiscal Q3 earnings Tuesday of $0.69 per share, up from $0.65 a year earlier. Four analysts polled by FactSet expected $0.64. Net sales for the quarter ended Oct. 27 were $2.04 billion, up from $1.83 billion a year earlier. Analysts surveyed by FactSet expected $1.99 billion....
BRIEF-Accord Biopharma Announces Agreement By Intas Pharmaceuticals, Ltd. To Acquire Udenyca® (Pegfilgrastim-Cbqv) Business From Coherus Biosciences, Inc., Unlocking Potential For Continued U.S. Growt
BRIEF-Accord Biopharma Announces Agreement By Intas Pharmaceuticals, Ltd. To Acquire Udenyca® (Pegfilgrastim-Cbqv) Business From Coherus Biosciences, Inc., Unlocking Potential For Continued U.S. Growt
Dec 3, 2024
Dec 3 (Reuters) - * ACCORD BIOPHARMA ANNOUNCES AGREEMENT BY INTAS PHARMACEUTICALS, LTD. TO ACQUIRE UDENYCA® (PEGFILGRASTIM-CBQV) BUSINESS FROM COHERUS BIOSCIENCES, INC., UNLOCKING POTENTIAL FOR CONTINUED U.S. GROWTH Source text: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved